US20040151763A1 - Wipe formulation - Google Patents

Wipe formulation Download PDF

Info

Publication number
US20040151763A1
US20040151763A1 US10/753,797 US75379704A US2004151763A1 US 20040151763 A1 US20040151763 A1 US 20040151763A1 US 75379704 A US75379704 A US 75379704A US 2004151763 A1 US2004151763 A1 US 2004151763A1
Authority
US
United States
Prior art keywords
formulation
present
agent
total weight
group
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US10/753,797
Inventor
Catherine Durden
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Egdewell Personal Care Brands LLC
Playtex Products LLC
Original Assignee
Playtex Products LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Playtex Products LLC filed Critical Playtex Products LLC
Priority to US10/753,797 priority Critical patent/US20040151763A1/en
Assigned to GENERAL ELECTRIC CAPITAL CORPORATION, AS AGENT reassignment GENERAL ELECTRIC CAPITAL CORPORATION, AS AGENT SECURITY INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: PLAYTEX PRODUCTS, INC.
Assigned to WELLS FARGO BANK MINNESOTA, NATIONAL ASSOCIATION reassignment WELLS FARGO BANK MINNESOTA, NATIONAL ASSOCIATION SECURITY INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: PLAYTEX PRODUCTS, INC.
Publication of US20040151763A1 publication Critical patent/US20040151763A1/en
Assigned to GE CANADA FINANCE HOLDING COMPANY reassignment GE CANADA FINANCE HOLDING COMPANY SECURITY INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: PLAYTEX PRODUCTS, INC.
Assigned to PLAYTEX PRODUCTS, INC, TANNING RESEARCH LABORATORIES, INC reassignment PLAYTEX PRODUCTS, INC RELEASE BY SECURED PARTY (SEE DOCUMENT FOR DETAILS). Assignors: GE CANADA FINANCE HOLDING COMPANY, GENERAL ELECTRIC CAPITAL CORPORATION, WELLS FARGO BANK, NATIONAL ASSOCIATION
Assigned to EVEREADY BATTERY COMPANY, LLC reassignment EVEREADY BATTERY COMPANY, LLC CHANGE OF NAME (SEE DOCUMENT FOR DETAILS). Assignors: EVEREADY BATTERY COMPANY, INC
Assigned to EGDEWELL PERSONAL CARE BRANDS, LLC reassignment EGDEWELL PERSONAL CARE BRANDS, LLC CHANGE OF NAME (SEE DOCUMENT FOR DETAILS). Assignors: EVEREADY BATTERY COMPANY, LLC
Abandoned legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61QSPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00Preparations for care of the skin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00Cosmetics or similar toiletry preparations
    • A61K8/02Cosmetics or similar toiletry preparations characterised by special physical form
    • A61K8/0208Tissues; Wipes; Patches
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00Cosmetics or similar toiletry preparations
    • A61K8/18Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/33Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
    • A61K8/36Carboxylic acids; Salts or anhydrides thereof
    • A61K8/365Hydroxycarboxylic acids; Ketocarboxylic acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00Cosmetics or similar toiletry preparations
    • A61K8/18Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/96Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
    • A61K8/97Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
    • A61K8/9783Angiosperms [Magnoliophyta]
    • A61K8/9789Magnoliopsida [dicotyledons]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/02Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • A61P15/02Drugs for genital or sexual disorders; Contraceptives for disorders of the vagina
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2800/00Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
    • A61K2800/74Biological properties of particular ingredients
    • A61K2800/75Anti-irritant
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0034Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants

Definitions

  • the present invention relates to a formulation for a wipe. More particularly, the present invention relates to a wipe or towelette formulation that has an anti-irritant agent.
  • the wipe is particularly useful for feminine cleansing, and may alternatively be used for adult personal hygiene.
  • a towelette or wipe is generally an absorbent sheet that is treated or pre-moistened with a liquid formulation.
  • the liquid used in pre-moistening the sheet is generally an aqueous solution.
  • the solution may have a surface active detergent, a humectant and, in some instances, also a fragrance.
  • U.S. Pat. No. 5,804,203 to Hahn et al. is directed to a topical composition for reducing skin irritation in animals comprising an irritant ingredient and an anti-irritant amount of aqueous-soluble strontium cation.
  • U.S. Pat. No. 4,772,501 to Johnson et al. is directed to a wet wipe product having a fibrous wipe, a liquid preservative composition, and an enclosure for the fibrous wipe and the liquid preservative composition.
  • the liquid preservative composition consists essentially of: (a) a mixture of citric acid and sorbic acid as the preservative component; (b) water; and (c) optional ingredients selected from the group consisting of skin moisturizers and fragrance compounds.
  • a mild wipe formulation that comprises an anti-irritant agent, citric acid and at least one preservative.
  • the wipe formulation comprises an anti-irritant agent, a pH adjuster, namely citric acid, at least one preservative, and one or more of the following: a humectant, a surfactant, a skin conditioning agent, an emulsifying agent, a chelating agent, a second preservative that specifically prevents mold, and a fragrance.
  • the present invention is a liquid wipe formulation. This formulation is used primarily in a feminine wipe.
  • the wipe formulation has an anti-irritant agent, a pH adjuster, namely citric acid, and at least one preservative.
  • the anti-irritant agent used in the present wipe formulation has been effective to clean, refresh and prevent further feminine itching.
  • the anti-irritant agent is preferably one or more of the following: local anesthetics, analgesics, anesthetics, antipruitics, astringents, hydrocortisone preparations, keratolytics or any combinations thereof.
  • the local anesthetics that can be used in the present invention include benzocaine, benzyl alcohol, dibucaine, dibucaine HCl, Dyclonine HCl, Lidocaine, Pramoxine HCl, Tetracaine, Tetracaine HCl, or any combinations thereof.
  • the anti-irritant agent is preferably present in an amount from about 1 wt % up to about 50 wt % of the total weight of the liquid, wipe formulation. More preferably, the anti-irritant agent is preferably present in an amount about 9 wt % of the total weight of the liquid, wipe formulation.
  • the anti-irritant agent is an anesthetic
  • it is preferably a mixture of the following local anesthetics, and preferably in the approximate amount, set forth below.
  • Local Anesthetics in percentage by wt (wt %) of the wipe formulation Benzocaine 5.0-20.0 Benzyl alcohol 1.0-4.0 Dibucaine 0.25-1.0 Dibucaine HCl 0.25-1.0
  • the analgesic, anesthetic or antipruitic anti-irritant agents that can be used in the present wipe formulation include camphor, juniper tar, menthol or combinations thereof.
  • the anti-irritant agent is an analgesic, an anesthetic or an antipruitic, it is preferably in the following mixture, and in an approximate range, set forth below.
  • Analgesic, anesthetic and antipruitic in wt % of the wipe formulation Camphor 0.1-3.0 Juniper tar 1.0-5.0 Menthol 0.1-1.0
  • the astringents that can be used in the present wipe formulation include calamine, zinc oxide or any combination thereof.
  • the anti-irritant agent is an astringent, it is preferably in the following mixture, and preferably in the approximate range, set forth below.
  • Astringents in wt % of the wipe formulation Calamine 5.0-25.0 Zinc oxide 5.0-25.0 Witch hazel 1.0-50.0
  • hydrocortisone preparations that can be used in the present wipe formulation include hydrocortisone, hydrocortisone acetate or any combination thereof. If the anti-irritant agent is a hydrocortisone preparation, it is preferably present in the following mixture, and preferably in the approximate range, set forth below. Hydrocortisone preparations in wt % of the wipe formulation Hydrocortisone 0.25-0.5 Hydrocortisone 0.25-0.5 acetate
  • the keratolytics that can be used in the present wipe formulation include alcloxa, resorcinol or any combination thereof.
  • the anti-irritant agent is a keratolytic, it is preferably present the following mixture, and preferably in the approximate range, set forth below. Keratolytics in wt % of the wipe formulation Alcloxa 0.2-2.0 Resorcinol 1.0-3.0
  • the second ingredient of the present wipe formulation is a pH adjuster.
  • the preferred pH adjuster is citric acid.
  • citric acid is present in an amount from about 0.01 wt % to about 1 wt % of the total weight of the liquid, wipe formulation. More preferably, the citric acid is present in an amount from about 0.05 wt % to about 0.5 wt %, and most preferably about 0.1 wt %, of the total weight of the wipe formulation.
  • the wipe formulation is in a pH range from about 4.0 to about 6.0, and preferably from about 4.5 to about 5.0.
  • the present wipe formulation has at least one preservative. That preservative is preferably one or more of the following: sodium hydroxymethylglycinate, polyaminopropyl biguanide, quaternary ammonium compound, EDTA salt, EDTA fatty acid conjugate, alkanol especially ethanol, isopropyl alcohol, benzyl alcohol, paraben, sorbate, urea derivative, and isothiazolinone, or any combination thereof.
  • the preferred preservative is sodium hydroxymethylglycinate.
  • the preservative is preferably present in an amount from about 0.2 wt % to about 2 wt %, and more preferably about 0.5 wt %, of the total weight of the wipe formulation.
  • the liquid wipe formulation has an anti-irritant agent, a pH adjuster, namely citric acid, and at least one preservative.
  • the wipe formulation has the anti-irritant, the pH adjuster, namely citric acid, the at least one preservative, and one or more of the following ingredients: a humectant, a surfactant, a skin conditioning agent, an emulsifying agent, a chelating agent, a second preservative which specifically prevents mold, and a fragrance.
  • the liquid wipe formulation includes the anti-irritant, the pH adjuster, namely citric acid, the at least one preservative, a humectant, a surfactant, a skin conditioning agent, an emulsifying agent, a chelating agent, a second preservative which specifically prevents mold, and a fragrance.
  • the humectant used in a wipe of the present invention is preferably one or more of the following: glycerol, propylene glycol, sorbitol urea, amino acid, polyol and other compounds with hygroscopic properties, or any combination thereof.
  • the preferred humectant is propylene glycol.
  • the humectant is preferably present in an amount from about 0.1 wt % up to about 2 wt % of the total weight of the liquid, wipe formulation. More preferably, the humectant is present in an amount about 0.5 wt %.
  • the surfactant that can be used in a wipe formulation of the present invention is preferably one or more of the following: alkylamido alkylamine, quaternary ammonium compound, phosphorus derivative, amphoteric imidazoline derivative, fatty sulfosuccinate ester and amide, ethoxylated sorbitan ester, betaine, alkoxylated alcohol, alkyl ether sulfate, disodium cocoamphodiacetate, cocamidopropyl betaine, PEG-80 glyceryl cocoate/PEG-30 glyceryl cocoate, decyl polyglucose, or any combinations thereof.
  • the preferred surfactant is disodium cocoamphodiacetate.
  • the surfactant is preferably present in an amount greater than about 0 to about 1 wt % of the total weight of the liquid, wipe formulation. More preferably, the surfactant is present in an amount about 0.10 wt % of the total weight of the wipe formulation.
  • the skin conditioning agent used in an embodiment of the present wipe formulation is preferably one or more of the following: botanical extract including aloe vera gel, ester including tocopherol acetate (vitamin E acetate), quaternary ammonium compound, asymmetrical carbonate, N-substituted carboxamide, urea or phosphine oxide, organic salt, or any combination thereof.
  • the skin conditioning agent is preferably present in an amount greater than about 0 wt % up to about 1.25 wt % of the total weight of the liquid, wipe formulation. More preferably, it is present in an amount about 0.02 wt % of the wipe formulation.
  • the preferred skin conditioning agents are aloe vera gel and tocopheryl acetate.
  • aloe vera gel When used, aloe vera gel is preferably present in an amount greater than about 0 to about 1 wt % of the total weight of the liquid formulation. More preferably, it is present in an amount about 0.01 wt %.
  • tocopheryl acetate (vitamin E acetate) is preferably present in an amount greater than about 0 to about 1.0 wt % of the total weight of the liquid formulation. More preferably, it is present in an amount about 0.01 wt % of the wipe formulation.
  • the emulsifying agent used in a wipe formulation of the present invention is any one or more of the following: sorbitan, alkoxylated fatty alcohol, alkylpolyglycoside, soap, alkyl sulfate, monoalkyl and dialkyl phosphate, alkyl sulphonate, acyl isothionate, or any combinations thereof.
  • the preferred emulsifying agent is polysorbate 20.
  • the emulsifying agent is preferably present in an amount greater than about 0 wt % to about 1 wt % of the total weight of the liquid, wipe formulation. More preferably, it is present in an amount about 0.25 wt % of the wipe formulation.
  • the chelating agent that can be used in a present wipe formulation is preferably one or more of the following: disodium EDTA (ethylenediamine tetraacetate), ethylene-diamine-tetra-acetic acid, (ethylenedioxy)-diethylene-dinitrilo-tetra-acetic acid, salicylaldoxime, quinolinol, triethylenetetramine, or any combinations thereof.
  • the preferred chelating agent is disodium EDTA.
  • the chelating agent is preferably present in an amount greater than about 0 wt % up to about 0.2 wt % of the total weight of the liquid, wipe formulation. More preferably, the chelating agent is present in an amount about 0.1 wt % of the wipe formulation.
  • a wipe formulation of the present invention may include a second preservative that is specifically present to prevent mold.
  • the preferred second preservative is potassium sorbate.
  • the second preservative is preferably present in an amount from about 0.1 wt % to about 0.3 wt % of the total weight of the liquid, wipe formulation. More preferably, the second preservative is present in an amount about 0.14 wt % of the wipe formulation.
  • a wipe formulation of the present invention may include a fragrance. Any conventional fragrance that is mild and does not adversely affect sensitive areas for females, or other adults, may be used. Preferably, the fragrance is present in an amount greater than about 0 wt % up to about 0.5 wt %, and more preferably about 0.05 wt %, of the total weight of the liquid, wipe formulation.
  • the wipe formulations of the present invention have therapeutic benefits. In addition, they prevent or minimize skin irritation and itching. Moreover, each of the wipe formulations of the present invention is mild. The wipe formulations of the present invention may be used as a feminine wipe and, in particular, prevent or minimize feminine itching.

Abstract

The present invention relates to a liquid formulation for a feminine wipe. The preferred formulation has an anti-irritant agent, a pH adjuster namely citric acid, and at least one preservative.

Description

    BACKGROUND OF THE INVENTION
  • 1. Field of the Invention [0001]
  • The present invention relates to a formulation for a wipe. More particularly, the present invention relates to a wipe or towelette formulation that has an anti-irritant agent. The wipe is particularly useful for feminine cleansing, and may alternatively be used for adult personal hygiene. [0002]
  • 2. Description of the Prior Art [0003]
  • A towelette or wipe is generally an absorbent sheet that is treated or pre-moistened with a liquid formulation. The liquid used in pre-moistening the sheet is generally an aqueous solution. The solution may have a surface active detergent, a humectant and, in some instances, also a fragrance. [0004]
  • U.S. Pat. No. 5,804,203 to Hahn et al. is directed to a topical composition for reducing skin irritation in animals comprising an irritant ingredient and an anti-irritant amount of aqueous-soluble strontium cation. [0005]
  • U.S. Pat. No. 4,772,501 to Johnson et al. is directed to a wet wipe product having a fibrous wipe, a liquid preservative composition, and an enclosure for the fibrous wipe and the liquid preservative composition. The liquid preservative composition consists essentially of: (a) a mixture of citric acid and sorbic acid as the preservative component; (b) water; and (c) optional ingredients selected from the group consisting of skin moisturizers and fragrance compounds. [0006]
  • SUMMARY OF THE INVENTION
  • It is an object of the present invention to provide a mild formulation for use in a wipe. [0007]
  • It is another object of the present invention to provide a mild wipe formulation that has an anti-irritant agent. [0008]
  • It is a further object of the present invention to provide such a mild wipe formulation that prevents or minimizes skin irritation and itching especially feminine itching. [0009]
  • These and other objects and advantages of the present invention are achieved by a mild wipe formulation that comprises an anti-irritant agent, citric acid and at least one preservative. In one embodiment of the present invention, the wipe formulation comprises an anti-irritant agent, a pH adjuster, namely citric acid, at least one preservative, and one or more of the following: a humectant, a surfactant, a skin conditioning agent, an emulsifying agent, a chelating agent, a second preservative that specifically prevents mold, and a fragrance.[0010]
  • DETAILED DESCRIPTION OF THE INVENTION
  • The present invention is a liquid wipe formulation. This formulation is used primarily in a feminine wipe. The wipe formulation has an anti-irritant agent, a pH adjuster, namely citric acid, and at least one preservative. [0011]
  • The anti-irritant agent used in the present wipe formulation has been effective to clean, refresh and prevent further feminine itching. The anti-irritant agent is preferably one or more of the following: local anesthetics, analgesics, anesthetics, antipruitics, astringents, hydrocortisone preparations, keratolytics or any combinations thereof. The local anesthetics that can be used in the present invention include benzocaine, benzyl alcohol, dibucaine, dibucaine HCl, Dyclonine HCl, Lidocaine, Pramoxine HCl, Tetracaine, Tetracaine HCl, or any combinations thereof. The anti-irritant agent is preferably present in an amount from about 1 wt % up to about 50 wt % of the total weight of the liquid, wipe formulation. More preferably, the anti-irritant agent is preferably present in an amount about 9 wt % of the total weight of the liquid, wipe formulation. [0012]
  • When the anti-irritant agent is an anesthetic, it is preferably a mixture of the following local anesthetics, and preferably in the approximate amount, set forth below. [0013]
    Local Anesthetics in percentage
    by wt (wt %) of the wipe
    formulation
    Benzocaine  5.0-20.0
    Benzyl alcohol 1.0-4.0
    Dibucaine 0.25-1.0 
    Dibucaine HCl 0.25-1.0 
    Dyclonine HCl 0.5-1.0
    Lidocaine 2.0-5.0
    Pramoxine HCl 1.0
    Tetracaine 0.5-1.0
    Tetracaine HCl 0.5-1.0
  • The analgesic, anesthetic or antipruitic anti-irritant agents that can be used in the present wipe formulation include camphor, juniper tar, menthol or combinations thereof. When the anti-irritant agent is an analgesic, an anesthetic or an antipruitic, it is preferably in the following mixture, and in an approximate range, set forth below. [0014]
    Analgesic, anesthetic and
    antipruitic in wt % of the wipe
    formulation
    Camphor 0.1-3.0
    Juniper tar 1.0-5.0
    Menthol 0.1-1.0
  • The astringents that can be used in the present wipe formulation include calamine, zinc oxide or any combination thereof. When the anti-irritant agent is an astringent, it is preferably in the following mixture, and preferably in the approximate range, set forth below. [0015]
    Astringents in wt % of the wipe
    formulation
    Calamine 5.0-25.0
    Zinc oxide 5.0-25.0
    Witch hazel 1.0-50.0
  • The hydrocortisone preparations that can be used in the present wipe formulation include hydrocortisone, hydrocortisone acetate or any combination thereof. If the anti-irritant agent is a hydrocortisone preparation, it is preferably present in the following mixture, and preferably in the approximate range, set forth below. [0016]
    Hydrocortisone preparations in
    wt % of the wipe formulation
    Hydrocortisone 0.25-0.5
    Hydrocortisone 0.25-0.5
    acetate
  • The keratolytics that can be used in the present wipe formulation include alcloxa, resorcinol or any combination thereof. When the anti-irritant agent is a keratolytic, it is preferably present the following mixture, and preferably in the approximate range, set forth below. [0017]
    Keratolytics in wt % of the wipe
    formulation
    Alcloxa 0.2-2.0
    Resorcinol 1.0-3.0
  • The second ingredient of the present wipe formulation is a pH adjuster. The preferred pH adjuster is citric acid. Preferably, citric acid is present in an amount from about 0.01 wt % to about 1 wt % of the total weight of the liquid, wipe formulation. More preferably, the citric acid is present in an amount from about 0.05 wt % to about 0.5 wt %, and most preferably about 0.1 wt %, of the total weight of the wipe formulation. With the above amounts of pH adjuster, the wipe formulation is in a pH range from about 4.0 to about 6.0, and preferably from about 4.5 to about 5.0. [0018]
  • The present wipe formulation has at least one preservative. That preservative is preferably one or more of the following: sodium hydroxymethylglycinate, polyaminopropyl biguanide, quaternary ammonium compound, EDTA salt, EDTA fatty acid conjugate, alkanol especially ethanol, isopropyl alcohol, benzyl alcohol, paraben, sorbate, urea derivative, and isothiazolinone, or any combination thereof. The preferred preservative is sodium hydroxymethylglycinate. The preservative is preferably present in an amount from about 0.2 wt % to about 2 wt %, and more preferably about 0.5 wt %, of the total weight of the wipe formulation. [0019]
  • In one embodiment of the present invention, the liquid wipe formulation has an anti-irritant agent, a pH adjuster, namely citric acid, and at least one preservative. In another embodiment of the present invention, the wipe formulation has the anti-irritant, the pH adjuster, namely citric acid, the at least one preservative, and one or more of the following ingredients: a humectant, a surfactant, a skin conditioning agent, an emulsifying agent, a chelating agent, a second preservative which specifically prevents mold, and a fragrance. In yet another embodiment of the present invention, the liquid wipe formulation includes the anti-irritant, the pH adjuster, namely citric acid, the at least one preservative, a humectant, a surfactant, a skin conditioning agent, an emulsifying agent, a chelating agent, a second preservative which specifically prevents mold, and a fragrance. [0020]
  • The humectant used in a wipe of the present invention is preferably one or more of the following: glycerol, propylene glycol, sorbitol urea, amino acid, polyol and other compounds with hygroscopic properties, or any combination thereof. The preferred humectant is propylene glycol. The humectant is preferably present in an amount from about 0.1 wt % up to about 2 wt % of the total weight of the liquid, wipe formulation. More preferably, the humectant is present in an amount about 0.5 wt %. [0021]
  • The surfactant that can be used in a wipe formulation of the present invention is preferably one or more of the following: alkylamido alkylamine, quaternary ammonium compound, phosphorus derivative, amphoteric imidazoline derivative, fatty sulfosuccinate ester and amide, ethoxylated sorbitan ester, betaine, alkoxylated alcohol, alkyl ether sulfate, disodium cocoamphodiacetate, cocamidopropyl betaine, PEG-80 glyceryl cocoate/PEG-30 glyceryl cocoate, decyl polyglucose, or any combinations thereof. The preferred surfactant is disodium cocoamphodiacetate. The surfactant is preferably present in an amount greater than about 0 to about 1 wt % of the total weight of the liquid, wipe formulation. More preferably, the surfactant is present in an amount about 0.10 wt % of the total weight of the wipe formulation. [0022]
  • The skin conditioning agent used in an embodiment of the present wipe formulation is preferably one or more of the following: botanical extract including aloe vera gel, ester including tocopherol acetate (vitamin E acetate), quaternary ammonium compound, asymmetrical carbonate, N-substituted carboxamide, urea or phosphine oxide, organic salt, or any combination thereof. The skin conditioning agent is preferably present in an amount greater than about 0 wt % up to about 1.25 wt % of the total weight of the liquid, wipe formulation. More preferably, it is present in an amount about 0.02 wt % of the wipe formulation. The preferred skin conditioning agents are aloe vera gel and tocopheryl acetate. When used, aloe vera gel is preferably present in an amount greater than about 0 to about 1 wt % of the total weight of the liquid formulation. More preferably, it is present in an amount about 0.01 wt %. When used, tocopheryl acetate (vitamin E acetate) is preferably present in an amount greater than about 0 to about 1.0 wt % of the total weight of the liquid formulation. More preferably, it is present in an amount about 0.01 wt % of the wipe formulation. [0023]
  • The emulsifying agent used in a wipe formulation of the present invention is any one or more of the following: sorbitan, alkoxylated fatty alcohol, alkylpolyglycoside, soap, alkyl sulfate, monoalkyl and dialkyl phosphate, alkyl sulphonate, acyl isothionate, or any combinations thereof. The preferred emulsifying agent is polysorbate 20. The emulsifying agent is preferably present in an amount greater than about 0 wt % to about 1 wt % of the total weight of the liquid, wipe formulation. More preferably, it is present in an amount about 0.25 wt % of the wipe formulation. [0024]
  • The chelating agent that can be used in a present wipe formulation is preferably one or more of the following: disodium EDTA (ethylenediamine tetraacetate), ethylene-diamine-tetra-acetic acid, (ethylenedioxy)-diethylene-dinitrilo-tetra-acetic acid, salicylaldoxime, quinolinol, triethylenetetramine, or any combinations thereof. The preferred chelating agent is disodium EDTA. The chelating agent is preferably present in an amount greater than about 0 wt % up to about 0.2 wt % of the total weight of the liquid, wipe formulation. More preferably, the chelating agent is present in an amount about 0.1 wt % of the wipe formulation. [0025]
  • A wipe formulation of the present invention may include a second preservative that is specifically present to prevent mold. The preferred second preservative is potassium sorbate. The second preservative is preferably present in an amount from about 0.1 wt % to about 0.3 wt % of the total weight of the liquid, wipe formulation. More preferably, the second preservative is present in an amount about 0.14 wt % of the wipe formulation. [0026]
  • A wipe formulation of the present invention may include a fragrance. Any conventional fragrance that is mild and does not adversely affect sensitive areas for females, or other adults, may be used. Preferably, the fragrance is present in an amount greater than about 0 wt % up to about 0.5 wt %, and more preferably about 0.05 wt %, of the total weight of the liquid, wipe formulation. [0027]
  • The one example of the subject liquid wipe formulation is listed in Table 1 in weight percents, along with acceptable ranges. [0028]
    TABLE 1
    Subject
    Formulation Ranges*
    Ingredient (wt %) (wt %)
    Water QS QS
    Witch Hazel 9  1-50
    Propylene Glycol 0.5 0.1-2  
    Disodium Cocoamphodiacetate 0.1 0-1
    Tocopheryl Acetate (Vitamin E 0.01 0-1
    Acetate)
    Aloe Vera Gel 0.01 0-1
    Fragrance 0.05   0-0.5
    Polysorbate 20 0.25   0-0.5
    Preservative 0.5 0.2-2  
    Disodium EDTA 0.1   0-0.2
    Potassium Sorbate 0.14 0.1-0.3
    Citric Acid 0.1 0.01-1  
    TOTAL 100 100
  • The wipe formulations of the present invention have therapeutic benefits. In addition, they prevent or minimize skin irritation and itching. Moreover, each of the wipe formulations of the present invention is mild. The wipe formulations of the present invention may be used as a feminine wipe and, in particular, prevent or minimize feminine itching. [0029]
  • It should be understood that the foregoing description is only illustrative of the present invention. Various alternatives and modifications can be devised by those skilled in the art without departing from the invention. Accordingly, the present invention is intended to embrace all such alternatives, modifications and variances that fall within the scope of the appended claims. [0030]

Claims (29)

What is claimed is:
1. A liquid formulation for a wipe comprising an anti-irritant agent, citric acid, and at least one preservative.
2. The formulation of claim 1, wherein said anti-irritant agent is selected from the group consisting of anesthetic, analgesic, antipruitic, astringent, hydrocortisone preparation, keratolytic, and any combinations thereof.
3. The formulation of claim 1, wherein said anti-irritant agent is at least one local anesthetic selected from the group consisting of: benzocaine, benzyl alcohol, dibucaine, dibucaine HCl, Dyclonine HCl, Lidocaine, Pramoxine HCl, Tetracaine, Tetracaine HCl, and any combinations thereof.
4. The formulation of claim 1, wherein said anti-irritant agent is at least one analgesic, anesthetic, or antipruitic selected from the group consisting of camphor, juniper tar, menthol, and any combinations thereof.
5. The formulation of claim 1, wherein said anti-irritant agent is at least one hydrocortisone derivative selected from the group consisting of hydrocortisone, hydrocortisone acetate, and any combination thereof.
6. The formulation of claim 1, wherein said anti-irritant agent is at least one keratolytic selected from the group consisting of alcloxa, resorcinol, and any combination thereof.
7. The formulation of claim 1, wherein said anti-irritant agent is at least one astringent selected from the group consisting of witch hazel, calamine, zinc oxide, and any combinations thereof.
8. The formulation of claim 1, wherein said anti-irritant agent is witch hazel.
9. The formulation of claim 1, wherein said anti-irritant agent is present in an amount from about 1 wt % up to about 50 wt % of the total weight of the formulation.
10. The formulation of claim 9, wherein said anti-irritant agent is present in an amount about 9 wt % of the total weight of the formulation.
11. The formulation of claim 1, wherein said citric acid is present in an amount from 0.01 wt % to 1 wt % of the total weight of the formulation.
12. The formulation of claim 1, wherein the formulation is in a pH range from about 4.0 to about 6.0.
13. The formulation of claim 1, wherein said at least one preservative is present in an amount from about 0.2 wt % to about 2 wt % of the total weight of the formulation.
14. The formulation of claim 1, wherein said at least one preservative is sodium hydroxymethylglycinate.
15. The formulation of claim 1, further comprising a humectant selected from the group consisting of glycerol, propylene glycol, sorbitol urea, amino acid, polyol, other compounds with hygroscopic properties, and any combinations thereof.
16. The formulation of claim 15, wherein said humectant is present in an amount from about 0.1 wt % to about 2 wt % of the total weight of the formulation.
17. The formulation of claim 1, further comprising a surfactant selected from the group consisting of alkylamido alkylamine, quaternary ammonium compound, phosphorus derivative, amphoteric imidazoline derivative, fatty sulfosuccinate ester and amide, ethoxylated sorbitan ester, betaine, alkoxylated alcohol, alkyl ether sulfate, disodium cocoamphodiacetate, cocamidopropyl betaine, PEG-80 glyceryl cocoate/PEG-30 glyceryl cocoate, decyl polyglucose, and any combinations thereof
18. The formulation of claim 17, wherein said surfactant is present in an amount greater than about 0 wt % to about 1 wt % of the total weight of the formulation.
19. The formulation of claim 1, further comprising a skin conditioning agent selected from the group consisting of botanical extract, ester, quaternary ammonium compound, asymmetrical carbonate, N-substituted carboxamide, urea, phosphine oxide, organic salt, and any combinations thereof.
20. The formulation of claim 19, wherein the skin conditioning agent is in an amount greater than about 0 wt % up to about 1.25 wt % of the total weight of the formulation.
21. The formulation of claim 1, further comprising an emulsifying agent selected from the group consisting of: sorbitan, alkoxylated fatty alcohol, alkylpolyglycoside, soap, alkyl sulfate, monoalkyl and dialkyl phosphate, alkyl sulphonate, acyl isothionate, and any combinations thereof.
22. The formulation of claim 21, wherein the emulsifying agent is in an amount greater than about 0 wt % to about 1 wt % of the total weight of the formulation.
23. The formulation of claim 1, further comprising a second preservative that combats mold.
24. The formulation of claim 23, wherein said second preservative is in an amount from about 0.1 wt % to about 0.3 wt % of the total weight of the formulation.
25. The formulation of claim 23, wherein said second preservative is potassium sorbate.
26. The formulation of claim 1, further comprising a chelating agent selected from the group consisting of disodium EDTA, ethylene-diamine-tetra-acetic acid, (ethylenedioxy)-diethlyene-dinitrilo-tetra-acetic acid, salicylaldoxime, quinolinol, triethylenetetramine, and any combinations thereof.
27. The formulation of claim 26, wherein said chelating agent is present in an amount greater than about 0 wt % up to about 0.2 wt % of the total weight of the formulation.
28. The formulation of claim 1, further comprising a fragrance.
29. A liquid formulation for a wipe comprising citric acid, at least one preservative and an anti-irritant agent derived from a family selected from a group consisting of local anesthetic, analgesic, anesthetic, antipruitic, astringent, hydrocortisone preparation, and keratolytic, and any combinations thereof, wherein the wipe is a feminine wipe.
US10/753,797 2001-10-01 2004-01-08 Wipe formulation Abandoned US20040151763A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US10/753,797 US20040151763A1 (en) 2001-10-01 2004-01-08 Wipe formulation

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US09/968,200 US6737068B2 (en) 2001-10-01 2001-10-01 Wipe formulation
US10/753,797 US20040151763A1 (en) 2001-10-01 2004-01-08 Wipe formulation

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
US09/968,200 Continuation US6737068B2 (en) 2001-10-01 2001-10-01 Wipe formulation

Publications (1)

Publication Number Publication Date
US20040151763A1 true US20040151763A1 (en) 2004-08-05

Family

ID=25513896

Family Applications (2)

Application Number Title Priority Date Filing Date
US09/968,200 Expired - Lifetime US6737068B2 (en) 2001-10-01 2001-10-01 Wipe formulation
US10/753,797 Abandoned US20040151763A1 (en) 2001-10-01 2004-01-08 Wipe formulation

Family Applications Before (1)

Application Number Title Priority Date Filing Date
US09/968,200 Expired - Lifetime US6737068B2 (en) 2001-10-01 2001-10-01 Wipe formulation

Country Status (5)

Country Link
US (2) US6737068B2 (en)
AU (1) AU2002337677B2 (en)
CA (1) CA2462510C (en)
MX (1) MXPA04003088A (en)
WO (1) WO2003028600A1 (en)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013164713A1 (en) * 2012-04-30 2013-11-07 Kimberly-Clark Worldwide, Inc. Anti-adherent formulation including a quaternary ammonium compound and a fatty alcohol
WO2015092609A1 (en) * 2013-12-20 2015-06-25 Pfizer Inc. Pre-moistened wipes for use in treating anal-rectal irritations and disorders
WO2019140422A1 (en) * 2018-01-15 2019-07-18 Sanit Technologies Llc Anti-microbial soap

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2844455B1 (en) * 2002-09-13 2007-12-14 Lab Francais Du Fractionnement TREATMENT OF PATHOLOGIES EXCLUDING IMMUNE RESPONSE BY OPTIMIZED ANTIBODIES
US20060051428A1 (en) * 2004-09-03 2006-03-09 Nelson Ayala Aspartame and citrate flavored phosphate salt laxative
US20060062832A1 (en) * 2004-09-20 2006-03-23 Lopes John A Sanitizing wipes with microbicidal properties cross-reference to related applications
US7604997B2 (en) * 2005-01-18 2009-10-20 The United States Of America As Represented By The Department Of Health And Human Services Wipes and methods for removal of metal contamination from surfaces
US20060171971A1 (en) * 2005-02-01 2006-08-03 The Procter & Gamble Company Composition for wet wipes containing a non-irritating skin health benefit ingredient and the process for making
US20070082061A1 (en) * 2005-10-07 2007-04-12 Nelson Ayala Reduction of saltiness with sweeteners
US7985429B2 (en) * 2006-03-03 2011-07-26 C. B. Fleet Company, Inc. Flavored colonic cleansing system
US20090053290A1 (en) * 2006-03-08 2009-02-26 Sand Bruce J Transdermal drug delivery compositions and topical compositions for application on the skin
US7998510B2 (en) 2006-08-17 2011-08-16 C. B. Fleet Company, Inc. Low dose colonic cleansing system
EP1980241B1 (en) 2007-04-04 2015-10-14 Mibelle AG Wet wipes with vitex agnus castus extract for feminine personal care
WO2008133868A1 (en) * 2007-04-23 2008-11-06 Safe N' Simple Stoma wipe and adhesive remover and method
US20080260806A1 (en) * 2007-04-23 2008-10-23 Risa Miller Personal hygiene compositions and methods
US8648027B2 (en) 2012-07-06 2014-02-11 The Clorox Company Low-VOC cleaning substrates and compositions comprising a cationic biocide
CA2916297C (en) 2013-06-27 2018-07-10 The Procter & Gamble Company Personal care compositions and articles
WO2015084880A1 (en) 2013-12-03 2015-06-11 Kimberly-Clark Worldwide, Inc. Wet wipes for personal care
US9096821B1 (en) 2014-07-31 2015-08-04 The Clorox Company Preloaded dual purpose cleaning and sanitizing wipe
US10264788B2 (en) * 2015-12-30 2019-04-23 Carefusion 2200, Inc. Antimicrobial wipe
US10975341B2 (en) 2017-09-18 2021-04-13 The Clorox Company Cleaning wipes having particular MABDF characteristics
US10973385B2 (en) 2017-09-18 2021-04-13 The Clorox Company Cleaning wipes having particular pore volume distribution characteristics
US10973386B2 (en) 2017-09-18 2021-04-13 The Clorox Company Cleaning wipes system having particular performance characteristics
US10982177B2 (en) 2017-09-18 2021-04-20 The Clorox Company Cleaning wipes with particular lotion retention and efficacy characteristics
US11273625B2 (en) 2018-12-21 2022-03-15 The Clorox Company Process for manufacturing multi-layer substrates comprising sandwich layers and polyethylene

Family Cites Families (60)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2565887A (en) 1946-06-21 1951-08-28 Ivers Lee Co Sheathed flexible sheet
US3414927A (en) 1966-10-10 1968-12-10 Gurdon S. Worcester Composite web for treating human tissue
US3786615A (en) 1972-11-13 1974-01-22 Pfizer Process for preparing pre-moistened antimicrobial towels
US4309469A (en) 1977-08-22 1982-01-05 Scott Paper Company Flushable binder system for pre-moistened wipers wherein an adhesive for the fibers of the wipers interacts with ions contained in the lotion with which the wipers are impregnated
US4383986A (en) 1981-08-17 1983-05-17 Ortho Pharmaceutical Corporation Hemorrhoidal compositions
US4615937A (en) 1985-09-05 1986-10-07 The James River Corporation Antimicrobially active, non-woven web used in a wet wiper
US4737405A (en) 1985-09-30 1988-04-12 James River Corporation Binder catalyst for an antimicrobially active, non-woven web
IL78566A (en) 1986-04-22 1989-07-31 Porat Amir Towelette
US4781974A (en) 1986-04-23 1988-11-01 James River Corporation Antimicrobially active wet wiper
US4865221A (en) 1986-07-30 1989-09-12 Kimberly-Clark Corporation Wet wipe and wipe dispensing arrangement
US4741944A (en) 1986-07-30 1988-05-03 Kimberly-Clark Corporation Wet wipe and wipe dispensing arrangement
DE3630392C1 (en) 1986-09-06 1988-02-11 Rhodia Ag Process for the production of consolidated nonwovens
US4732797A (en) 1987-02-27 1988-03-22 James River Corporation Wet wiper natural acid preservation system
US4772501A (en) 1987-02-27 1988-09-20 James River Corporation Wet wiper natural acid preservation system
US6033679A (en) 1998-04-27 2000-03-07 The Procter & Gamble Company Uncomplexed cyclodextrin compositions for odor control
US5141803A (en) * 1988-06-29 1992-08-25 Sterling Drug, Inc. Nonwoven wipe impregnating composition
US4941995A (en) 1988-07-05 1990-07-17 Scott Paper Company Natural preservative composition for wet wipes
US4904524A (en) 1988-10-18 1990-02-27 Scott Paper Company Wet wipes
US5049440A (en) 1989-07-28 1991-09-17 The James River Corporation Wet wiper natural acid and salt preservative composition
US5733572A (en) 1989-12-22 1998-03-31 Imarx Pharmaceutical Corp. Gas and gaseous precursor filled microspheres as topical and subcutaneous delivery vehicles
US5219646A (en) 1990-05-11 1993-06-15 E. I. Du Pont De Nemours And Company Polyester blends and their use in compostable products such as disposable diapers
US5152996A (en) 1990-12-10 1992-10-06 Eastman Kodak Company Nonwoven wipes impregnated with an aqueous solution of a zinc acetate peroxide and a surfactant
US5215759A (en) 1991-10-01 1993-06-01 Chanel, Inc. Cosmetic composition
US5449763A (en) 1991-10-10 1995-09-12 Henkel Corporation Preparation of alkylpolyglycosides
EP0613369A1 (en) 1991-11-22 1994-09-07 Richardson-Vicks, Inc. Combined personal cleansing and moisturizing compositions
US5256417A (en) 1992-01-31 1993-10-26 Air Products And Chemicals, Inc. Water dispersible towelette impregnated with non-aqueous lotion formulations
TW311085B (en) 1993-03-18 1997-07-21 Dymon Inc
US5447930A (en) * 1993-05-06 1995-09-05 Warner-Lambert Company Topical anesthetic compositions
US5635469A (en) 1993-06-10 1997-06-03 The Procter & Gamble Company Foaming cleansing products
US5407958A (en) * 1993-07-30 1995-04-18 Beauticontrol Cosmetics, Inc. Therapeutic skin composition
US5512199A (en) 1993-11-02 1996-04-30 Becton Dickinson And Company Hand wipe solution
JPH09510185A (en) 1993-12-23 1997-10-14 ザ、プロクター、エンド、ギャンブル、カンパニー Tissue moisturizing and antimicrobial composition
ATE199215T1 (en) 1993-12-23 2001-03-15 Procter & Gamble ANTIMICROBIAL COMPOSITIONS FOR WIPES
AU705862B2 (en) 1994-02-28 1999-06-03 Incline Technologies, Inc. Method and system for cleansing the skin
AU685302B2 (en) 1994-06-29 1998-01-15 Ecolab Inc. Composition and improved pH driven method for wastewater separation using an amphoteric carboxylate and a cationic destabilizer composition
US5607678A (en) 1994-08-24 1997-03-04 The Procter & Gamble Company Mild shower gel composition comprising unique thickener system which imparts improved lathering properties and modified rinse feel
EP0777464A1 (en) 1994-08-26 1997-06-11 The Procter & Gamble Company Personal cleansing compositions
US5534265A (en) 1994-08-26 1996-07-09 The Procter & Gamble Company Thickened nonabrasive personal cleansing compositions
US5507968A (en) 1994-12-14 1996-04-16 Minnesota Mining And Manufacturing Company Cleansing articles with controlled detergent release and method for their manufacture
US5716625A (en) 1994-12-21 1998-02-10 Cosmederm Technologies Formulations and methods for reducing skin irritation
US5804203A (en) 1994-12-21 1998-09-08 Cosmederm Technologies Topical product formulations containing strontium for reducing skin irritation
WO1996020712A1 (en) * 1994-12-30 1996-07-11 American Home Products Corporation Clear non-alcoholic hydrocortisone solutions
US5648083A (en) 1995-02-10 1997-07-15 The Procter & Gamble Company Personal care compositions and wipe products containing the compositions
US5629081A (en) 1995-03-31 1997-05-13 Kimberly-Clark Tissue Corporation Premoistened, flushable, disposable and biodegradable wet wipes
JP3669758B2 (en) 1995-06-15 2005-07-13 ユニ・チャーム株式会社 Lid device
US5665364A (en) 1995-07-24 1997-09-09 The Procter & Gamble Company Compositions for topical delivery of active ingredients
ZA966814B (en) 1995-08-18 1998-02-12 Colgate Palmolive Co Clear cosmetic gel composition.
US5753246A (en) 1995-11-20 1998-05-19 Peters; Marlin W. Packaged germicidal towelette, sanitation kit and method for promoting hygiene
US6015816A (en) 1996-02-29 2000-01-18 The Research Foundation Of State University Of New York Antimicrobial compositions
US6001344A (en) 1996-03-06 1999-12-14 Lever Brothers Company Liquid cleansing compositions comprising xanthan gum and cross-linked polyacrylic acid polymers for enhanced suspension of large droplet oils
US5736128A (en) 1996-05-14 1998-04-07 Isp Investments Inc. Cosmetic composition for rejuvenation of skin without skin irritation
EP0912098B2 (en) 1996-07-16 2011-01-19 The Procter & Gamble Company Use of a combination of surfactants, chelating agents and essential oils for effective disinfection
US5897856A (en) * 1996-10-24 1999-04-27 The Procter & Gamble Company Methods and compositions for reducing body odor
US5939050A (en) 1997-04-04 1999-08-17 Optiva Corp. Antimicrobial compositions
US5968539A (en) 1997-06-04 1999-10-19 Procter & Gamble Company Mild, rinse-off antimicrobial liquid cleansing compositions which provide residual benefit versus gram negative bacteria
US5942214A (en) 1997-06-09 1999-08-24 The Procter & Gamble Company Methods for controlling environmental odors on the body using compositions comprising uncomplexed cyclodextrins and perfume
US6015547A (en) 1997-10-27 2000-01-18 Church & Dwight Co., Inc. Stable solution of zinc ions and bicarbonate and/or carbonate ions
US5993792A (en) 1997-11-13 1999-11-30 Tiro Industries Incorporated System for customized hair products containing surfactants
US6042839A (en) 1998-03-09 2000-03-28 Color Access, Inc. Powder compositions
US5915394A (en) 1998-08-10 1999-06-29 Rickard; Peter Fragrance towelette

Cited By (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013164713A1 (en) * 2012-04-30 2013-11-07 Kimberly-Clark Worldwide, Inc. Anti-adherent formulation including a quaternary ammonium compound and a fatty alcohol
GB2515696A (en) * 2012-04-30 2014-12-31 Kimberly Clark Co Anti-adherent formulation including a quaternary ammonium compound and a fatty alcohol
GB2515696B (en) * 2012-04-30 2020-11-25 Kimberly Clark Co Use of an anti-adherent formulation including a quaternary ammonium compound and a fatty alcohol
KR101819843B1 (en) * 2013-12-20 2018-01-17 화이자 인코포레이티드 Pre-moistened wipes for use in treating anal-rectal irritations and disorders
JP2016540804A (en) * 2013-12-20 2016-12-28 ファイザー・インク Pre-wet wipes for use in the treatment of anorectal inflammation and disorders
TWI607767B (en) * 2013-12-20 2017-12-11 輝瑞股份有限公司 Pre-moistened wipes for use in treating anal-rectal irritations and disorders
CN105828789A (en) * 2013-12-20 2016-08-03 辉瑞大药厂 Pre-moistened wipes for use in treating anal-rectal irritations and disorders
RU2646489C2 (en) * 2013-12-20 2018-03-05 Пфайзер Инк. Pre-moistened wipes for use in treatment of anorectal irritations and disorders
US10238704B2 (en) 2013-12-20 2019-03-26 Pfizer Inc. Pre moistened wipes for use in treating anal rectal irritations and disorders
CN110251438A (en) * 2013-12-20 2019-09-20 辉瑞大药厂 For treating the cleaning piece of anal orifice and rectal intestine stimulation and obstacle soaked in advance
WO2015092609A1 (en) * 2013-12-20 2015-06-25 Pfizer Inc. Pre-moistened wipes for use in treating anal-rectal irritations and disorders
US11376293B2 (en) 2013-12-20 2022-07-05 Pf Consumer Healthcare 1 Llc Pre-moistened wipes for use in treating anal rectal irritations and disorders
WO2019140422A1 (en) * 2018-01-15 2019-07-18 Sanit Technologies Llc Anti-microbial soap

Also Published As

Publication number Publication date
CA2462510C (en) 2010-08-24
MXPA04003088A (en) 2004-07-08
WO2003028600B1 (en) 2003-09-18
CA2462510A1 (en) 2003-04-10
US6737068B2 (en) 2004-05-18
WO2003028600A1 (en) 2003-04-10
AU2002337677B2 (en) 2003-04-14
US20030072789A1 (en) 2003-04-17

Similar Documents

Publication Publication Date Title
US6737068B2 (en) Wipe formulation
AU2002337677A1 (en) Wipe formulation
US4420484A (en) Basic amino or ammonium antimicrobial agent-polyethylene glycol ester surfactant-betaine and/or amine oxide surfactant compositions and method of use therof
ES2206714T3 (en) COMPOSITION FOR SKIN WASHING.
US4197316A (en) Treatment of dry skin
CA2142419A1 (en) Composition
US7169400B2 (en) Waterless lotion and lotion-treated substrate
US4224319A (en) Antiseptic composition for topical application to the skin
DE2740349C2 (en)
US6641826B2 (en) Wipe with improved cleansing
US6579514B1 (en) Anti infective periodontic compositions
KR20030026233A (en) Skin cleanser containing anti-aging active
AU2001270161A1 (en) Wipe with improved cleansing
US5000868A (en) Surfactant compositions
USRE32300E (en) Basic amino or ammonium antimicrobial agent-polyethylene glycol ester surfactant-betaine and/or amine oxide surfactant compositions and method of use thereof
US8685906B2 (en) Low irritancy cleansing compositions
CN109195592B (en) Compositions, kits and methods for maintaining eyelid hygiene
EP1557161A1 (en) Method for cleansing sensitive skin using an alkanolamine
CA2145968A1 (en) Topical antipruritic composition
Belsito et al. Safety assessment of alkyl betaines as used in cosmetics
JPS62280297A (en) Low irritant detergent composition
US20200390673A1 (en) Composition for neutralizing or reducing effects of self-defense sprays
CN112675107A (en) Anorectal wet tissue and preparation method thereof
CN112545916A (en) Mild surfactant system and application thereof
Marks Jr et al. Safety Assessment of Alkyl Betaines as Used in Cosmetics

Legal Events

Date Code Title Description
AS Assignment

Owner name: GENERAL ELECTRIC CAPITAL CORPORATION, AS AGENT, CO

Free format text: SECURITY INTEREST;ASSIGNOR:PLAYTEX PRODUCTS, INC.;REEL/FRAME:014394/0685

Effective date: 20040219

Owner name: GENERAL ELECTRIC CAPITAL CORPORATION, AS AGENT,CON

Free format text: SECURITY INTEREST;ASSIGNOR:PLAYTEX PRODUCTS, INC.;REEL/FRAME:014394/0685

Effective date: 20040219

AS Assignment

Owner name: WELLS FARGO BANK MINNESOTA, NATIONAL ASSOCIATION,

Free format text: SECURITY INTEREST;ASSIGNOR:PLAYTEX PRODUCTS, INC.;REEL/FRAME:014990/0309

Effective date: 20040219

Owner name: WELLS FARGO BANK MINNESOTA, NATIONAL ASSOCIATION,C

Free format text: SECURITY INTEREST;ASSIGNOR:PLAYTEX PRODUCTS, INC.;REEL/FRAME:014990/0309

Effective date: 20040219

AS Assignment

Owner name: GE CANADA FINANCE HOLDING COMPANY,CANADA

Free format text: SECURITY INTEREST;ASSIGNOR:PLAYTEX PRODUCTS, INC.;REEL/FRAME:016862/0334

Effective date: 20051128

Owner name: GE CANADA FINANCE HOLDING COMPANY, CANADA

Free format text: SECURITY INTEREST;ASSIGNOR:PLAYTEX PRODUCTS, INC.;REEL/FRAME:016862/0334

Effective date: 20051128

STCB Information on status: application discontinuation

Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION

AS Assignment

Owner name: PLAYTEX PRODUCTS, INC, CONNECTICUT

Free format text: RELEASE BY SECURED PARTY;ASSIGNORS:GENERAL ELECTRIC CAPITAL CORPORATION;GE CANADA FINANCE HOLDING COMPANY;WELLS FARGO BANK, NATIONAL ASSOCIATION;SIGNING DATES FROM 20071001 TO 20071007;REEL/FRAME:043230/0546

Owner name: TANNING RESEARCH LABORATORIES, INC, FLORIDA

Free format text: RELEASE BY SECURED PARTY;ASSIGNORS:GENERAL ELECTRIC CAPITAL CORPORATION;GE CANADA FINANCE HOLDING COMPANY;WELLS FARGO BANK, NATIONAL ASSOCIATION;SIGNING DATES FROM 20071001 TO 20071007;REEL/FRAME:043230/0546

AS Assignment

Owner name: EVEREADY BATTERY COMPANY, LLC, MISSOURI

Free format text: CHANGE OF NAME;ASSIGNOR:EVEREADY BATTERY COMPANY, INC;REEL/FRAME:043571/0118

Effective date: 20150625

Owner name: EGDEWELL PERSONAL CARE BRANDS, LLC, MISSOURI

Free format text: CHANGE OF NAME;ASSIGNOR:EVEREADY BATTERY COMPANY, LLC;REEL/FRAME:043571/0987

Effective date: 20150629